Navigation Links
Reportlinker Adds Successful Strategies for Drug Repositioning

NEW YORK, April 20, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Successful Strategies for Drug Repositioning


This report Highlights how drug repositioning can provide a low-risk approach to drug development. The success of the approach is illustrated by a number of case histories, mostly arising from serendipitous observations. The report illustrates systematic approaches to identify suitable opportunities that should lead to better success including those being pursued by specialist companies.

Features and benefits

* Analyze and understand the strategies employed in the most successful examples of drug repositioning.

* Discover the key technologies required to establish potential repositioning opportunities.

* Identify the specialist service providers with expertise in the key technologies required to systematically identify repositioning candidates.

* Discover how through repositioning a company can protect its intellectual property.

* Analyze the potential impact that drug repositioning can have on both large pharma companies and small specialist companies.


The pharma industry's revenue growth is low and it is failing to introduce sufficient new drugs to offset the impact of patent expirations despite record R&D costs. Repurposing of drugs offers a lower risk, lower cost, approach to new product development. Repurposing of development failures can recover what would otherwise be lost R&D expenditure.

The potential commercial benefits from successful repositioning of a drug are likely to be greater than those offered by simple reformulation, and offers opportunities for extended periods of market exclusivity via the granting of additional patents.

Major companies are well positioned to benefit from the successful repurposing of drugs, especially when they utilize both internal resources and external resources. The effective application of repurposing technologies should enable major companies to significantly enhance their development pipelines.

Your key questions answered

* What are the current advantages of repositioning over other lower risk approaches to drug development?

* What are the key technologies being used to identify new targets for molecules in companies' databases?

* How does drug repositioning improve the intellectual property position of companies that employ this strategy?

* What skills and platforms do specialist companies engaged in drug repositioning possess?

* How have molecules such as sildenafil and thalidomide been repositioned successfully?


Executive Summary

Chapter 1 Introduction

Chapter 2 Lower Risk Strategies

Chapter 3 What is Repositioning?

Chapter 4 Strategic Approaches to Repositioning

Chapter 5 Successful case studies

Chapter 6 Current Efforts

Chapter 7 Specialist Companies

Chapter 8 Outlook

About the author





The decline in approvals of novel chemical entities

The costs, and risks, of drug development

Lower Risk Strategies



Enantiomeric switches

Active metabolites



What is Repositioning?



Commercial implications

Intellectual property issues

Design or serendipity?

Strategic Approaches to Repositioning



Chemical space

New indications

Phenotypic approaches

Informatics-based approaches


Exploiting intellectual property

Increased licensing opportunities

Successful case studies







sildenafil (Viagra and Revatio)

Current Efforts



Major opportunities

Rare diseases

Drugs in advanced development

Inhaled formulations

Biological products

Modified formulations

Repurposing by combination

Other approaches

Specialist Companies



Almac Group

Ampio Pharmaceuticals

Anaxomics Biotech

APT Pharmaceuticals

Aureus Sciences



Cypress Bioscience


Horizon Discovery

Jenken Biosciences

Melior Discovery

NeuroHealing Pharmaceuticals




Ore Pharmaceutical Holdings

Radical Therapeutix

SOM Biotech

Somaxon Pharmaceuticals

Sosei Group

SWITCH Biotech

Tangent Reprofiling





Impact on major companies

Impact for specialist companies

Overall perspective




To order this report:

: Successful Strategies for Drug Repositioning

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Middle Eastern Medical Device Market: Facts and Figures2011
2. Reportlinker Adds Levosimendan - Comprehensive patent search
3. Reportlinker Adds Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)
4. Reportlinker Adds North America Dental Devices Market Outlook to 2017
5. Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
6. Reportlinker Adds ENT Devices Market Outlook in United States to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
7. Reportlinker Adds Companion Diagnostics Partnering Terms and Agreements
8. Reportlinker Adds ENT Devices Market Outlook in China to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
9. Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
10. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
11. Reportlinker Adds Arthritis Therapy Area Pipeline Report
Post Your Comments:
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted ... in Chicago, IL, UV Angel is evaluating the efficacy of its product and its ... units (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving ... has dropped below 10,000 for the first time since 2011. In 2014, there were ... to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
Breaking Medicine News(10 mins):